Online ISSN: 1949-2553
About Oncotarget
Our mission is to make scientific results rapidly and widely available. We seek to maximize the impact of research via insightful review, to enable exceptional discoveries to be shared quickly, to eliminate the border between specialties, to link different fields of biomedical science, and to foster application of basic and clinical science to fight disease.

Oncotarget | Continuous Treatment With Abemaciclib Leads to Sustained and Efficient Inhibition of Breast Cancer Cell Proliferation

News

July 6, 2022
PRESS RELEASE: On July 2, a new research paper was published in Oncotarget, entitled, “Continuous treatment with abemaciclib leads to sustained and efficient inhibition of breast cancer cell proliferation." continue reading »

Oncotarget | New Oncology-Focused Papers Published in Volume 13

News

June 23, 2022
PRESS RELEASE: As of June 23, 2022, Oncotarget has published a total of 64 high-impact, oncology-focused papers within Volume 13. continue reading »

Behind the Study: IGF-pathway Biomarkers and Lung Cancer

Oncotarget

June 14, 2022
Dr. Alexander Pohlman from Rush Medical College, Rush University Medical Center, Chicago, IL, describes a recent review published by Oncotarget that he co-authored entitled, “The role of IGF-pathway biomarkers in determining risks, screening, and prognosis in lung cancer.” continue reading »

A Novel Group of Genes That Cause Endocrine Resistance in Breast Cancer Identified by Dynamic Gene Expression Analysis

News

June 8, 2022
A research paper was recently published in Oncotarget, entitled, “A novel group of genes that cause endocrine resistance in breast cancer identified by dynamic gene expression analysis.” continue reading »

New Tool Uses NF-κB Activity to Classify HPV+ Head and Neck Cancer

Oncotarget

May 26, 2022
Researchers developed a new tool aimed at better classifying HPV+ HNSCC patients with good or poor prognosis in an effort to personalize treatment and improve patient outcomes. continue reading »